Literature DB >> 17570603

Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD.

Miranda Olff1, Giel-Jan de Vries, Yener Güzelcan, Johanna Assies, Berthold P R Gersons.   

Abstract

Post-traumatic stress disorder (PTSD) has been associated with dysregulation of the neuroendocrine system. In this study we examine the effects of psychotherapy in 21 PTSD patients, with and without coexisting depression, on the levels of six stress-related hormones: cortisol, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone-sulfate (DHEA-S), prolactin, thyrotropin (TSH) and free thyroxin (fT4). The results show that after brief eclectic psychotherapy (BEP) significant changes occurred in levels of cortisol and DHEA. Responders showed an increase in cortisol and DHEA levels, while in non-responders both hormone levels decreased. Differences were only found after controlling for depressive symptoms. In conclusion, effective psychotherapy for PTSD may alter dysregulations in the Hypothalamus-pituitary-adrenal (HPA)-axis, but comorbid depressive symptoms should be taken into account.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570603     DOI: 10.1016/j.psyneuen.2007.04.001

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  38 in total

1.  Preclinical perspectives on posttraumatic stress disorder criteria in DSM-5.

Authors:  Susannah Tye; Elizabeth Van Voorhees; Chunling Hu; Timothy Lineberry
Journal:  Harv Rev Psychiatry       Date:  2015 Jan-Feb       Impact factor: 3.732

2.  Cortisol Response Following Exposure Treatment for PTSD in Rape Victims.

Authors:  Maryrose Gerardi; Barbara O Rothbaum; Millie C Astin; Mary Kelley
Journal:  J Aggress Maltreat Trauma       Date:  2010-06-01

3.  Glucocorticoid-related predictors and correlates of post-traumatic stress disorder treatment response in combat veterans.

Authors:  Rachel Yehuda; Laura C Pratchett; Matthew W Elmes; Amy Lehrner; Nikolaos P Daskalakis; Erin Koch; Iouri Makotkine; Janine D Flory; Linda M Bierer
Journal:  Interface Focus       Date:  2014-10-06       Impact factor: 3.906

Review 4.  Epigenetic and Neural Circuitry Landscape of Psychotherapeutic Interventions.

Authors:  Christopher W T Miller
Journal:  Psychiatry J       Date:  2017-05-25

5.  Effect of current and lifetime posttraumatic stress disorder on 24-h urinary catecholamines and cortisol: results from the Mind Your Heart Study.

Authors:  Katja Wingenfeld; Mary A Whooley; Thomas C Neylan; Christian Otte; Beth E Cohen
Journal:  Psychoneuroendocrinology       Date:  2014-11-05       Impact factor: 4.905

Review 6.  Neuroendocrine pathways underlying risk and resilience to PTSD in women.

Authors:  Meghna Ravi; Jennifer S Stevens; Vasiliki Michopoulos
Journal:  Front Neuroendocrinol       Date:  2019-09-19       Impact factor: 8.606

Review 7.  Individualized preventive psychiatry: syndrome and vulnerability diagnostics.

Authors:  Franz Müller-Spahn
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

8.  Children with disrupted attachment histories: interventions and psychophysiological indices of effects.

Authors:  Carlo Schuengel; Mirjam Oosterman; Paula S Sterkenburg
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-09-04       Impact factor: 3.033

9.  The association of dehydroepiandrosterone and dehydroepiandrosterone sulfate with anxiety sensitivity and electronic diary negative affect among smokers with and without posttraumatic stress disorder.

Authors:  Elizabeth E Van Voorhees; Michelle F Dennis; F Joseph McClernon; Patrick S Calhoun; Natalie A Buse; Jean C Beckham
Journal:  J Clin Psychopharmacol       Date:  2013-08       Impact factor: 3.153

10.  Adrenocortical responsiveness to infusions of physiological doses of ACTH is not altered in posttraumatic stress disorder.

Authors:  Allen D Radant; Dorcas J Dobie; Elaine R Peskind; M Michele Murburg; Eric C Petrie; Evan D Kanter; Murray A Raskind; Charles W Wilkinson
Journal:  Front Behav Neurosci       Date:  2009-10-30       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.